System for interstitial photodynamic therapy with online dosimetry: first clinical experiences of prostate cancer.
The first results from a clinical study for Temoporfin-mediated photodynamic therapy (PDT) of low-grade (T1c) primary prostate cancer using online dosimetry are presented. Dosimetric feedback in real time was applied, for the first time to our knowledge, in interstitial photodynamic therapy. The dosimetry software IDOSE provided dose plans, including optical fiber positions and light doses based on 3-D tissue models generated from ultrasound images. Tissue optical property measurements were obtained using the same fibers used for light delivery. Measurements were taken before, during, and after the treatment session. On the basis of these real-time measured optical properties, the light-dose plan was recalculated. The aim of the treatment was to ablate the entire prostate while minimizing exposure to surrounding organs. The results indicate that online dosimetry based on real-time tissue optical property measurements enabled the light dose to be adapted and optimized. However, histopathological analysis of tissue biopsies taken six months post-PDT treatment showed there were still residual viable cancer cells present in the prostate tissue sections. The authors propose that the incomplete treatment of the prostate tissue could be due to a too low light threshold dose, which was set to 5 J∕cm2.
SpectraCure AB, Magistratsvägen 10, SE-226 43 Lund, Sweden.
Johannes
J
Swartling
Johan
J
Axelsson
Göran
G
Ahlgren
Karl Mikael
KM
Kälkner
Sten
S
Nilsson
Sune
S
Svanberg
Katarina
K
Svanberg
Stefan
S
Andersson-Engels
D000368:Aged; D006801:Humans; D021621:Imaging, Three-Dimensional; D008279:Magnetic Resonance Imaging; D008297:Male; D008652:Mesoporphyrins / Q000627:therapeutic use; D008875:Middle Aged; D009862:Online Systems; D055620:Optical Phenomena; D019047:Phantoms, Imaging; D010778:Photochemotherapy / Q000295:instrumentation* / Q000379:methods; D017319:Photosensitizing Agents / Q000627:therapeutic use; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D011880:Radiotherapy Planning, Computer-Assisted
D008652:Mesoporphyrins; D017319:Photosensitizing Agents; D017430:Prostate-Specific Antigen; C072269:temoporfin